Certain therapies used for rheumatic diseases, including rituximab, are associated with worse outcomes for COVID-19 and reduced immune response after COVID-19 vaccination in patients with rheumatic diseases, according to two studies presented at the virtual EULAR 2021 Congress.
Eligible patients with rheumatic diseases (PRDs) are strongly urged to get vaccinated against COVID-19, and the vaccine may be administered while on immunomodulatory therapy, preferably during an inactive disease state, and without requiring testing for postvaccination antibody titres, according to recommendations from the Singapore Chapter of Rheumatologists.
Treatment with COVID-19 convalescent plasma (CCP) leads to a rapid increase in antibodies and is well tolerated in paediatric patients but does not seem to interfere with immune responses measured at 21 days, results of a recent study have shown.
Prehospital antibiotic therapy (PH-ABT) leads to a marked decrease in the overall rate of bacterial pathogen detection by culture, but not by polymerase chain reaction, in children with parapneumonic pleural effusion (PPE) and pleural empyema (PE), a study has found. PH-ABT also results in a reduced rate of infectious complications but does not have an impact on the overall disease duration.
Treatment with the HMG-CoA reductase inhibitor atorvastatin in critically ill patients with COVID-19 did not significantly reduce the primary composite outcome of venous or arterial thrombosis risk, treatment with extracorporeal membrane oxygenation (ECMO), or mortality vs placebo in the INSPIRATION-S study presented at ACC.21.
The human monoclonal antibody mavrilimumab reduced the rates of mechanical ventilation and death in nonmechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation, according to a phase II/III study presented at EULAR 2021.